BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 25246645)

  • 1. Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP.
    Nobile-Orazio E; Cocito D; Jann S; Uncini A; Messina P; Antonini G; Fazio R; Gallia F; Schenone A; Francia A; Pareyson D; Santoro L; Tamburin S; Cavaletti G; Giannini F; Sabatelli M; Beghi E;
    J Neurol Neurosurg Psychiatry; 2015 Jul; 86(7):729-34. PubMed ID: 25246645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial.
    Nobile-Orazio E; Cocito D; Jann S; Uncini A; Beghi E; Messina P; Antonini G; Fazio R; Gallia F; Schenone A; Francia A; Pareyson D; Santoro L; Tamburin S; Macchia R; Cavaletti G; Giannini F; Sabatelli M;
    Lancet Neurol; 2012 Jun; 11(6):493-502. PubMed ID: 22578914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone.
    Lopate G; Pestronk A; Al-Lozi M
    Arch Neurol; 2005 Feb; 62(2):249-54. PubMed ID: 15710853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined intravenous immunoglobulin and methylprednisolone as induction treatment in chronic inflammatory demyelinating polyneuropathy (OPTIC protocol): a prospective pilot study.
    Adrichem ME; Bus SR; Wieske L; Mohammed H; Verhamme C; Hadden R; van Schaik IN; Eftimov F
    Eur J Neurol; 2020 Mar; 27(3):506-513. PubMed ID: 31571349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in chronic inflammatory demyelinating polyradiculoneuropathy: protocol of an international, randomised, double-blind, placebo-controlled trial (OPTIC).
    Bus SRM; Zambreanu L; Abbas A; Rajabally YA; Hadden RDM; de Haan RJ; de Borgie CAJM; Lunn MP; van Schaik IN; Eftimov F;
    Trials; 2021 Feb; 22(1):155. PubMed ID: 33608058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
    Furukawa T; Kishiro M; Akimoto K; Nagata S; Shimizu T; Yamashiro Y
    Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of chronic inflammatory demyelinating polyneuropathy with high dose intravenous methylprednisolone monthly for five years: 10-Year follow up.
    Börü ÜT; Erdoğan H; Alp R; Taşdemir M; Yıldırım S; Bilgiç A; Duman A; Arslan A
    Clin Neurol Neurosurg; 2014 Mar; 118():89-93. PubMed ID: 24529237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
    van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS;
    Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Steroid pulse therapy].
    Miura M
    Nihon Rinsho; 2014 Sep; 72(9):1631-5. PubMed ID: 25518414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indirect-comparison meta-analysis of treatment options for patients with refractory Kawasaki disease.
    Chan H; Chi H; You H; Wang M; Zhang G; Yang H; Li Q
    BMC Pediatr; 2019 May; 19(1):158. PubMed ID: 31101091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Home IVIG for CIDP: a focus on patient centred care.
    Katzberg HD; Rasutis V; Bril V
    Can J Neurol Sci; 2013 May; 40(3):384-8. PubMed ID: 23603176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial.
    Ogata S; Ogihara Y; Honda T; Kon S; Akiyama K; Ishii M
    Pediatrics; 2012 Jan; 129(1):e17-23. PubMed ID: 22144699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relapse with Dysphagia in a Case of Chronic Inflammatory Demyelinating Polyradiculoneuropathy.
    Teramoto H; Morita A; Hara M; Ninomiya S; Shigihara S; Kusunoki S; Kamei S
    Intern Med; 2015; 54(14):1791-3. PubMed ID: 26179538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance IV immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy.
    Kuitwaard K; Fokkink WR; Brusse E; Vrancken AFJE; Eftimov F; Notermans NC; van der Kooi AJ; Merkies ISJ; Jacobs BC; van Doorn PA
    J Peripher Nerv Syst; 2017 Dec; 22(4):425-432. PubMed ID: 29092099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic inflammatory demyelinating polyneuropathy in patients with systemic lupus erythematosus: prognosis and outcome.
    Vina ER; Fang AJ; Wallace DJ; Weisman MH
    Semin Arthritis Rheum; 2005 Dec; 35(3):175-84. PubMed ID: 16325658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: the ICE trial.
    Hughes RA
    Expert Rev Neurother; 2009 Jun; 9(6):789-95. PubMed ID: 19496683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy.
    Marsh EA; Hirst CL; Llewelyn JG; Cossburn MD; Reilly MM; Krishnan A; Doran M; Ryan AM; Coles AJ; Jones JL; Robertson NP
    J Neurol; 2010 Jun; 257(6):913-9. PubMed ID: 20049473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: The ADVANCE-CIDP 1 randomized controlled trial.
    Bril V; Hadden RDM; Brannagan TH; Bar M; Chroni E; Rejdak K; Rivero A; Andersen H; Latov N; Levine T; Pasnoor M; Sacconi S; Souayah N; Anderson-Smits C; Duff K; Greco E; Hasan S; Li Z; Yel L; Ay H
    J Peripher Nerv Syst; 2023 Sep; 28(3):436-449. PubMed ID: 37314318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating lymphocyte and T memory subsets in glucocorticosteroid versus IVIG treated patients with CIDP.
    Klehmet J; Staudt M; Ulm L; Unterwalder N; Meisel A; Meisel C
    J Neuroimmunol; 2015 Jun; 283():17-22. PubMed ID: 26004151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe Chronic Inflammatory Demyelinating Polyneuropathy Ameliorated following High-dose (3 g/kg) Intravenous Immunoglobulin Therapy.
    Seino Y; Nakamura T; Hirohata M; Kawarabayashi T; Okushima T; Shoji M
    Intern Med; 2019 Mar; 58(6):855-859. PubMed ID: 30449785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.